Cingulate Inc

NASDAQ:CINGUnited States

Cingulate Inc. is a clinical stage biopharmaceutical company. The Company is focused on the development, manufacturing and commercialization of pharmaceutical products that utilize precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles that improves the lives of patients suffering from a multitude of commonly diagnosed conditions. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). Its CTx-1301 and CTx-1302 drug candidates both contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form. Its CTx-1301 and CTx-1302 that are being developed for the treatment of ADHD, in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+).

Contact Information

Headquarters

1901 W. 47Th PlaceKANSAS CITY, KS, United States 66205

Phone

913-942-2300

Fax

302-636-5454

Executives

Chairman of the Board, Chief Executive Officer, Co-Founder

Shane Schaffer

Co-Founder, Executive Vice President, Chief Science Officer

Raul Silva

Co-Founder, Executive Vice President, General Counsel, Secretary

Craig Gilgallon

Co-Founder, Executive Vice President, Chief Medical Officer

Matthew Brams

Chief Financial Officer, Executive Vice President

Louis Van Horn